Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2024 | Will blood-based biomarkers replace PET for trial recruitment?

Pamela Lukasewicz Ferreira • 8 Mar 2024
AD/PD 2024
Alzheimer’s Disease Dementia

Pamela Lukasewicz Ferreira, PhD, University of Pittsburgh, Pittsburgh, PA, briefly comments on the use of novel blood-based biomarkers for clinical trial enrolment screening. With emerging data emphasizing the relevance of tau levels for anti-amyloid therapy efficacy, markers capable to categorizing patients into low, intermediate, or high phosphorylated tau levels are of increasing importance. Currently, tau-PET can provide this information but blood-based biomarkers specific for tau pathology are yet to be validated. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Pamela Lukasewicz Ferreira

The impact of plasma p-tau217: pre-screening and selecting participants for AD trials
2:19
The impact of plasma p-tau217: pre-screening and selecting participants for AD trials
Pamela Lukasewicz Ferreira • 13 Jul 2026
Head-to-head comparison of the association of flortaucipir and MK6240 with plasma p-tau217 in AD
1:14
Head-to-head comparison of the association of flortaucipir and MK6240 with plasma p-tau217 in AD
Pamela Lukasewicz Ferreira • 13 Jul 2026
Cost-efficiency and feasibility of using plasma p-tau217 as a prescreening method in AD trials
2:05
Cost-efficiency and feasibility of using plasma p-tau217 as a prescreening method in AD trials
Pamela Lukasewicz Ferreira • 13 Jul 2026
Evolving use of tau-specific fluid biomarkers for Alzheimer's disease
1:15
Evolving use of tau-specific fluid biomarkers for Alzheimer's disease
Pamela Lukasewicz Ferreira • 8 Mar 2024

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals